You are thinking of patients while GILD is thinking of making max profit. I'm not even sure the 7% difference doesn't show stst-sig non inferiority to SOC and while I agree that the right way would be to separate GT2 and 3 and find a better combo for GT3, I think that in light of SOC, no options, no resistance, the FDA will approve.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.